What is the price of Noxopharm Limited (NOX)

The price of Noxopharm Limited (NOX) is $0.04443294

What is the market cap of Noxopharm Limited (NOX)

The market cap of Noxopharm Limited (NOX) is $13.65M

Noxopharm Limited (NOX) Earnings

Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.

Year	Earnings	Change
2026 (TTM)	$-4.15M	29.05%
2025	$-3.22M	-19.45%
2024	$-3.99M	-71.53%
2023	$-14.02M	-15.43%
2022	$-16.58M	136.55%
2021	$-7.01M	23.32%
2020	$-5.68M	-50.43%
2019	$-11.46M	-19.51%
2018	$-14.24M	507.24%
2017	$-2.35M	334.19%
2016	$-540.21K	0.00%

Year

Earnings

Change

2026 (TTM)

$-4.15M

29.05%

2025

$-3.22M

-19.45%

2024

$-3.99M

-71.53%

2023

$-14.02M

-15.43%

2022

$-16.58M

136.55%

2021

$-7.01M

23.32%

2020

$-5.68M

-50.43%

2019

$-11.46M

-19.51%

2018

$-14.24M

507.24%

2017

$-2.35M

334.19%

2016

$-540.21K

0.00%

Company	Earnings	Earnings Difference	Country
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-127,225.42%	US
Moderna, Inc. MRNA.US	$-3.09B	74,296.89%	US
CSL Limited CSL.AX	$-4.02B	96,690.59%	AU
Argenx SE ARGX.US	$1.95B	-47,110.79%	NL
Lonza Group AG LONN.SW	-	-	CH

Company

Earnings

Earnings Difference

Country